Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Alzheimer’s drug trials are fundamentally shifting toward intervening earlier in disease progression, using blood-based biomarkers for enrollment, and measuring slower cognitive decline rather than dramatic reversal. Instead of waiting for people to develop full-blown dementia symptoms, researchers now enroll participants in preclinical and mild cognitive impairment stages—often before they notice memory problems themselves. The success of lecanemab and donanemab, both amyloid-targeting monoclonal antibodies that showed modest slowing of decline in early-stage trials, has validated this approach and prompted the entire field to restructure how it designs, recruits for, and measures outcomes in Alzheimer’s studies.
This shift represents the most significant restructuring of Alzheimer’s research in decades, driven by decades of failed trials targeting symptomatic patients and a growing understanding that amyloid pathology begins years or decades before cognitive symptoms emerge. Blood tests for phosphorylated tau and amyloid ratios—once requiring expensive PET scans—now allow researchers to identify people at risk with a simple lab draw, dramatically expanding who can participate. The change means longer trials, more demanding monitoring schedules for participants, and a fundamental rethinking of what success looks like in a disease where current treatments cannot halt progression, only slow it.
Table of Contents
- Why Is Early Intervention the New Focus in Alzheimer’s Drug Development?
- How Are Blood Tests Changing Who Can Join Alzheimer’s Trials?
- What Structural Changes Are Happening in Trial Design and Timeline?
- How Are Combination Therapies Reshaping Trial Strategy?
- Why Is Measuring “Slowing Decline” More Complicated Than It Sounds?
- What Role Are Anti-Tau Antibodies Playing in the New Generation of Trials?
- How Are Recruitment Disparities Being Addressed in Modern Alzheimer’s Trials?
- Frequently Asked Questions
Why Is Early Intervention the New Focus in Alzheimer’s Drug Development?
For decades, Alzheimer’s trials enrolled people with cognitive complaints or mild to moderate dementia—the stages where brain damage was already substantial. These trials repeatedly failed because the neurodegeneration had progressed too far to be reversed or even substantially slowed. Researchers now understand that amyloid plaques and tau tangles accumulate silently for 10 to 20 years before anyone notices memory loss, and intervention during this “preclinical” window offers the best chance of meaningful benefit.
The Amyloid Biomarker Study (ABUS) and similar cohort studies have revealed that brain pathology begins measurably in cognitively normal people in their 50s and 60s, long before the first forgotten appointment. The Clarity AD trial of lecanemab exemplifies this shift: it enrolled 1,795 people with mild cognitive impairment or mild dementia due to Alzheimer’s disease who had confirmed amyloid on PET or tau pathology on biomarkers. Results showed a 27% slowing of decline over 18 months—a modest benefit, but one that previous symptomatic-stage trials had never achieved. This success triggered a cascade of earlier-stage trials: donanemab trials now focus on even earlier stages, including cognitively normal amyloid-positive people; anti-tau antibodies are moving into preclinical populations; and combination-therapy trials are launching to test amyloid and tau inhibitors together in early-stage cohorts.
How Are Blood Tests Changing Who Can Join Alzheimer’s Trials?
Blood biomarkers—specifically phosphorylated tau variants (p-tau181, p-tau217) and plasma phospho-tau-to-amyloid ratios—have transformed trial recruitment from an expensive, cumbersome process to something more feasible at scale. Previously, confirming amyloid pathology required an amyloid PET scan costing $3,000 to $5,000 and available only at major academic medical centers. Blood tests cost $200 to $500, can be drawn at any clinic or primary care office, and return results in days. This democratization means rural populations, people with limited transportation, and those without access to PET centers can now participate.
However, this expansion comes with a critical caveat: plasma biomarkers are becoming widely available before clinical utility is fully established for all variants. A person testing positive for elevated p-tau217 may have asymptomatic Alzheimer’s pathology but never develop symptoms in their lifetime. Blood tests can now identify people 15 to 20 years before cognitive decline, which is why preclinical trials now screen tens of thousands to identify thousands of preclinical amyloid-positive participants. The concern is that enrollment of asymptomatic biomarker-positive people may inflate perceived treatment benefits if some participants would never have progressed anyway.
What Structural Changes Are Happening in Trial Design and Timeline?
Traditional Alzheimer’s trials lasted 12 to 18 months and measured change in cognitive scores or functional ability. Modern trials now run 18 to 36 months to capture slower rates of change in less impaired populations—a preclinical participant declines far more slowly than someone with mild dementia. The AHEAD trial (Amyloid Biomarker Study), sponsored by the National Institute on Aging, plans 4 years of follow-up for cognitively normal amyloid-positive participants, versus 18 months for a mild dementia trial. Outcome measures have shifted too: instead of cognitive testing alone, trials now combine cognitive scores with biomarker changes on tau PET or blood phospho-tau, functional assessments, and neuropsychological batteries.
This lengthening places real burdens on participants. An 18-month trial with quarterly visits means 6 to 8 study visits; a 36-month preclinical trial means 12 to 16 visits including brain imaging, blood draws, and lengthy cognitive testing. Dropout rates in early-stage trials are often higher because asymptomatic participants feel less motivated by potential benefit and more burdened by the schedule. Dropouts introduce bias—if participants who decline fastest are more likely to leave, remaining participants look artificially stable. Some newer trials use at-home or telehealth cognitive testing and decentralized recruitment to reduce visit burden, though adherence to remote cognitive testing is still being validated.
How Are Combination Therapies Reshaping Trial Strategy?
A new generation of Alzheimer’s trials is testing two or three drugs simultaneously rather than running single-drug trials sequentially. The rationale is mechanistic: amyloid plaques and tau tangles are both present in most brains with Alzheimer’s pathology, and clearing one pathological protein alone has shown modest benefit. Combination trials now underway include amyloid monoclonal antibodies paired with anti-tau antibodies, or paired with secretase inhibitors that reduce amyloid production. These trials are larger, longer, and more complex to execute than single-drug studies.
The tradeoff is significant: if a combination therapy produces benefit, it’s difficult to discern which drug (or which interaction) drove the effect. A trial of amyloid antibody plus tau antibody that shows 35% slowing of decline cannot tell you whether amyloid alone, tau alone, or synergy between them produced the improvement. This design choice accelerates the path to treatments but may obscure mechanism and complicate future drug development. Additionally, combination therapies mean increased infusion burden—participants receiving two monoclonal antibodies may need two separate infusions per month, adding cost and dropout risk compared to a single-agent trial.
Why Is Measuring “Slowing Decline” More Complicated Than It Sounds?
Early amyloid-targeting trials, including Clarity AD, showed their benefit as a slowing of cognitive decline rather than stabilization or improvement. Lecanemab reduced the rate of decline by 27% over 18 months—meaning a person who would decline by 5 points on a cognitive scale might decline by 3.65 points instead. This benefit is real from a biomedical standpoint (less neurodegeneration), but its clinical meaningfulness remains debated. Some participants and families cannot perceive a 1.35-point difference in cognitive test scores over 18 months.
The challenge deepens in preclinical trials with cognitively normal participants: decline is even slower, and differentiating drug effect from natural test-retest variability requires massive sample sizes. An asymptomatic amyloid-positive person might score 29/30 on cognitive screening; 18 months later they score 28/30. Is that real decline, normal fluctuation, or a learning effect from repeated testing? Some preclinical trials now use biomarker slope—rate of change in plasma phospho-tau or tau PET burden—as a primary outcome instead of cognitive decline. This addresses statistical power but raises a new concern: slowing tau accumulation in a asymptomatic person’s bloodstream is not equivalent to preventing dementia, and regulatory agencies have not yet established how much biomarker change constitutes clinical benefit.
What Role Are Anti-Tau Antibodies Playing in the New Generation of Trials?
While amyloid-targeting monoclonal antibodies (lecanemab, donanemab, aducanumab) have dominated recent headlines, anti-tau antibodies represent the next mechanistic frontier. Tau is the second major hallmark pathology in Alzheimer’s disease—tangles of hyperphosphorylated tau inside neurons correlate more strongly with cognitive decline than plaques do. Several tau-targeting monoclonal antibodies and tau aggregation inhibitors are now in Phase 2 and Phase 3 trials: semorinemab, tirzepatide, and others targeting tau phosphorylation or propagation. Most of these are being tested in mild cognitive impairment or mild dementia stages, though preclinical tau trials are being planned.
The distinction matters for trial design: amyloid accumulates early and broadly in the cortex, making cognitively normal amyloid-positive people an accessible population for early trials. Tau pathology in early disease is more focal (concentrated in medial temporal lobe regions), and tau PET imaging is less standardized and more variable than amyloid PET. This means anti-tau trials may focus more on mild cognitive impairment and mild dementia stages where tau is more abundant and clinically relevant. Combination trials pairing amyloid and tau antibodies are now launching specifically to test whether addressing both pathologies earlier produces greater benefit than single-drug approaches.
How Are Recruitment Disparities Being Addressed in Modern Alzheimer’s Trials?
Historical Alzheimer’s trials enrolled predominantly white, college-educated, affluent participants from memory clinics at academic medical centers—a population unrepresentative of the broader dementia population. Black and Latino Americans, who experience higher prevalence of Alzheimer’s disease, were substantially underrepresented due to recruitment barriers including mistrust from historical research abuses, limited awareness of trial opportunities, transportation challenges, and language barriers. The AHEAD trial and newer anti-tau trials are implementing community-based recruitment, partnerships with underserved healthcare systems, and multilingual materials and staff to broaden enrollment.
Decentralized recruitment using direct-to-consumer advertising and at-home screening also expands participation beyond memory clinic populations. The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) trial, which enrolled 4,667 cognitively normal amyloid-positive participants, achieved roughly 30% participation from underrepresented racial and ethnic groups by using primary care physician referrals, community events, and web-based screening. However, even with these efforts, participants in major trials remain skewed toward higher education and higher income; cognitive testing and biomarker research are still more accessible to populations with resources and stable housing, and fully inclusive Alzheimer’s trials remain an unmet goal in the field.
Frequently Asked Questions
Can someone with no symptoms qualify for an Alzheimer’s drug trial?
Yes. Modern trials enroll cognitively normal people with amyloid or tau biomarkers detected on blood tests or imaging. These preclinical trials test whether early treatment can prevent symptom onset.
How long do current Alzheimer’s trials last?
Trials for mild cognitive impairment or mild dementia typically last 18 to 24 months with frequent visits. Preclinical trials may run 36 months or longer with quarterly or biannual assessments.
What does a 27% slowing of decline actually mean?
If a person would normally decline by 5 points on a cognitive test over 18 months, treatment might reduce that to 3.65 points. The difference is measurable but may not be noticeable in daily life.
Are blood biomarkers accurate enough to enroll people in trials?
Blood tests for phosphorylated tau and amyloid are highly accurate for research and enrollment, but positive results do not guarantee that someone will develop dementia; some people may remain cognitively normal for decades.
Why are combination drug trials starting now?
Because single-drug trials showed modest benefit, and Alzheimer’s pathology involves both amyloid and tau. Testing two drugs simultaneously may improve outcomes, though it complicates attribution of benefit.
